Drug General Information
Drug ID D03TFJ
Drug Name Benzimidazole
Synonyms BENZIMIDAZOLE; 51-17-2; 1H-Benzimidazole; 1H-Benzo[d]imidazole; 1,3-Benzodiazole; Benzoimidazole; o-Benzimidazole; 3-Azaindole; Benziminazole; Benzoglyoxaline; Azindole; 1,3-Diazaindene; 1H-Benzoimidazole; N,N'-Methenyl-o-phenylenediamine; NSC 759; Benzimidazol; 1H-1,3-benzodiazole; BZI; UNII-E24GX49LD8; CCRIS 5967; Benzimidazole, 98%; CHEBI:41275; HSDB 2797; EINECS 200-081-4; BRN 0109682; AI3-03737; E24GX49LD8; HYZJCKYKOHLVJF-UHFFFAOYSA-N; DSSTox_CID_4573; DSSTox_RID_77454; DSSTox_GSID_24573; F3366-5347; CAS-51-17-2; bezimidazole
Drug Type Small molecular drug
Structure D03TFJ
Drug Resistance Mutations
Target Name HCMV Tripartite terminase subunit 1 (UL56) Target Info
Gene Name UL56
Uniprot ID TRM1_HCMVA
Species Human cytomegalovirus
Reference Sequence MEMNLLQKLCVVCSKCNEYAMELECLKYCDPNVLLAESTPFKRNAAAIVYLYRKIYPEVV
AQNRTQSSLLTLYLEMLLKALHEDTALLDRALMAYSRQPDRAAFYRTVLRLDRCDRHHTV
ELQFTDNVRFSVSLATLNDIERFLCKMNYVYGILAPEAGLEVCAQLLELLRRLCGISPVA
RQEVYVEGTTCAQCYEELTIIPNQGRSLNKRLQGLLCNHIAVHRPSSQSDVNIQTVEQDL
LDLTTRIPHLAGVLSALKSLFSSSSAYHSYIQEAEEALREYNLFTDIPERIYSLSDFTYW
SRTSEVIVKRVGITIQQLNVYHQLCRALMNGISRHLYGEDVEDIFVLGEKALDGEERMFV
GSVFAAPNRIIDLITSLSIQAFEDNPVFNKLHESNEMYTKIKHILEEIRRPLPDGTGGDG
PEGEAIHLRGREAMSGTGTTLMTASNSSNSSTHSQRNNGGGGRARGGGKKVVGGGVNGQD
GDGSENGLRVRNCDEHEALDLVDARSRIHNVTREVNVRKRAYLQKVSEVGYGKVIRCIKT
QERLTSKLIDVNLVGPLCLDFISKLMNGFLYRSQYHQDQDVVDVGDQFTYDEHLYVVNNL
IHKSLPVESLPLLGQQIYELCNGPLFTHCTDRYPLSHNVDMAYACDNAGVLPHVKDDLVK
CAEGTVYPSEWMVVKYMGFFNFSDCQDLNVLQKEMWMHVRELVLSVALYNETFGKQLSIA
CLRDELHPDRDVILTYNKEWPLLLRHEGSLYKSKDLYLLLYRHLSRPDESGDVPTAPVAK
PSTLTAAAAVSGVFREPDRPWLPSPYPSSSTAGVSRRVRATRKRPRRASSLLDLARDEHG
IQDLVPGSLR [Human cytomegalovirus]
Targeted Disease Cytomegalovirus infection
Drug Resistance Mutations
Mutation info Missense: Q204R [1]
Level of Resistance Confer 10 fold resistance
Target Name HCMV Tripartite terminase subunit 1 + Tripartite terminase subunit 3 (UL56 + UL89) Target Info
Gene Name UL56 + UL89
Uniprot ID TRM1_HCMVM + TRM3_HCMVA
Species Human cytomegalovirus
Reference Sequence MEMNLLQKLCVVCSKCNEYAMELECLKYCDPNVLLAESTPFKRNAAAIVYLYRKIYPEVV
AQNRTQSSLLTLYLEMLLKALHEDTALLDRALMAYSRQPDRAAFYRTVLRLDRCDRHHTV
ELQFTDNVRFSVSLATLNDIERFLCKMNYVYGILAPEAGLEVCAQLLELLRRLCGISPVA
RQEVYVEGTTCAQCYEELTIIPNQGRSLNKRLQGLLCNHIAVHRPSSQSDVNIQTVEQDL
LDLTTRIPHLAGVLSALKSLFSSSSAYHSYIQEAEEALREYNLFTDIPERIYSLSDFTYW
SRTSEVIVKRVGITIQQLNVYHQLCRALMNGISRHLYGEDVEDIFVLGEKALDGEERMFV
GSVFAAPNRIIDLITSLSIQAFEDNPVFNKLHESNEMYTKIKHILEEIRRPLPDGTGGDG
PEGEVIHLRGREAMSGTGTTLMTASNSSNSSTHSQRNNGGGGRARGGGKKAVGGGANGQD
GDGSENGLRVRNCDEHEALDLVDARSRIHNVTREVNVRKRAYLQKVSEVGYGKVIRCIKT
QERLTSKLIDVNLVGPLCLDFISKLMNGFLYRSQYHQDQDVVDVGNQFTYDEHLYVVNNL
IHKSLPVESLPLLGQQIYELCNGPLFTHCTDRYPLSHNVDMAYACDNAGVLPHVKDDLVK
CAEGTVYPSEWMVVKYMGFFNFSDCQDLNVLQKEMWMHVRELVLSVALYNETFGKQLSIA
CLRDELHPDRDVILTYNKEWPLLLRHEGSLYKSKDLYLLLYRHLSRPDESGDVPTAPVAK
PSTLTAAAAVSGAFREPDRPWLPSPYPSSSTAGVSRRVRATRKRPRRASSLLDLARDEHG
IQDLVPGSLR; MLRGDSAAKIQERYAELQKRKSHPTSCISTAFTNVATLCRKRYQMMHP
ELGLAHSCNEAFLPLMAFCGRHRDYNSPEESQRELLFHERLKSALDKLTFRPCSEEQRAS
YQKLDALTELYRDPQFQQINNFMTDFKKWLDGGFSTAVEGDAKAIRLEPFQKNLLIHVIF
FIAVTKIPVLANRVLQYLIHAFQIDFLSQTSIDIFKQKATVFLVPRRHGKTWFIIPIISF
LLKHMIGISIGYVAHQKHVSQFVLKEVEFRCRHTFARDYVVENKDNVISIDHRGAKSTAL
FASCYNTNSIRGQNFHLLLVDEAHFIKKEAFNTILGFLAQNTTKIIFISSTNTTSDSTCF
LTRLNNAPFDMLNVVSYVCEEHLHSFTEKGDATACPCYRLHKPTFISLNSQVRKTANMFM
PGAFMDEIIGGTNKISQNTVLITDQSREEFDILRYSTLNTNAYDYFGKTLYVYLDPAFTT
NRKASGTGVAAVGAYRHQFLIYGLEHFFLRDLSESSEVAIAECAAHMIISVLSLHPYLDE
LRIAVEGNTNQAAAVRIACLIRQSVQSSTLIRVLFYHTPDQNHIEQPFYLMGRDKALAVE
QFISRFNSGYIKASQELVSYTIKLSHDPIEYLLEQIQNLHRVTLAEGTTARYSAKRQNRI
SDDLIIAVIMATYLCDDIHAIRFRVS [Human cytomegalovirus]
Targeted Disease Cytomegalovirus infection
Drug Resistance Mutations
Mutation info Missense: UL56:Q204R + UL89:D344E [1]
Level of Resistance Confer 30 fold resistance
Target Name HCMV Tripartite terminase subunit 3 (UL89) Target Info
Gene Name UL89
Uniprot ID TRM3_HCMVA
Species Human cytomegalovirus
Reference Sequence MLRGDSAAKIQERYAELQKRKSHPTSCISTAFTNVATLCRKRYQMMHPELGLAHSCNEAF
LPLMAFCGRHRDYNSPEESQRELLFHERLKSALDKLTFRPCSEEQRASYQKLDALTELYR
DPQFQQINNFMTDFKKWLDGGFSTAVEGDAKAIRLEPFQKNLLIHVIFFIAVTKIPVLAN
RVLQYLIHAFQIDFLSQTSIDIFKQKATVFLVPRRHGKTWFIIPIISFLLKHMIGISIGY
VAHQKHVSQFVLKEVEFRCRHTFARDYVVENKDNVISIDHRGAKSTALFASCYNTNSIRG
QNFHLLLVDEAHFIKKEAFNTILGFLAQNTTKIIFISSTNTTSDSTCFLTRLNNAPFDML
NVVSYVCEEHLHSFTEKGDATACPCYRLHKPTFISLNSQVRKTANMFMPGAFMDEIIGGT
NKISQNTVLITDQSREEFDILRYSTLNTNAYDYFGKTLYVYLDPAFTTNRKASGTGVAAV
GAYRHQFLIYGLEHFFLRDLSESSEVAIAECAAHMIISVLSLHPYLDELRIAVEGNTNQA
AAVRIACLIRQSVQSSTLIRVLFYHTPDQNHIEQPFYLMGRDKALAVEQFISRFNSGYIK
ASQELVSYTIKLSHDPIEYLLEQIQNLHRVTLAEGTTARYSAKRQNRISDDLIIAVIMAT
YLCDDIHAIRFRVS [Human cytomegalovirus]
Targeted Disease Cytomegalovirus infection
Drug Resistance Mutations
Mutation info Missense: D344E [1]
Level of Resistance Confer 10 fold resistance
References
REF 1 Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.